When a veterinary diagnostic laboratory returns an antimicrobial culture and susceptibility (C&S) report, clinicians and technicians are presented with a dense table: identified bacterial species, colony counts, a list of two dozen antibiotics, numerical Minimum Inhibitory Concentration (MIC) values, and bold letters—S (Susceptible), I (Intermediate), or R (Resistant).

For many general practitioners, veterinary nurses, and pet owners reviewing a lab PDF, the immediate temptation is to scan down the table, look for the lowest numerical MIC value, or pick the first broad-spectrum antibiotic marked with an "S".

This approach is one of the most common pitfalls in clinical medicine. The lowest numerical MIC is almost never the automatically superior antibiotic, and a "Susceptible" flag is not a mandate to prescribe a third-generation cephalosporin or fluoroquinolone when a narrow-spectrum first-line agent is clinically indicated.

A microbiology report is a standardized in vitro measurement judged against clinical breakpoints established by organizations such as the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Translating that laboratory result into an effective, safe, and responsible prescription requires a systematic, four-step reading sequence: organism identification and colony quantification first, infection-site pharmacology second, breakpoint distance third, and clinical practice guidelines fourth.

Below is an exhaustive reference guide to interpreting veterinary culture and sensitivity reports, explaining the mechanics of MICs and clinical breakpoints, avoiding classic misreads, integrating International Society for Companion Animal Infectious Diseases (ISCAID) stewardship guidelines, and understanding real-world resistance rates in canine pathogens.

Fast answer: The 4-step report reading sequence

When opening a veterinary microbiology report, follow this structured interpretation workflow:

1. Evaluate the organism and colony count (Is this a pathogen or a contaminant?):
   • Verify whether the organism matches the clinical presentation. A single isolate of Escherichia coli at >100,000 CFU/mL from a sterile cystocentesis is a confirmed pathogen; a mixed growth of three organisms at <1,000 CFU/mL from a voided "free-catch" urine sample or skin surface swab usually represents normal flora or collection contamination.
2. Determine anatomical drug penetration (Can the drug reach the site?):
   • Antibiotics distribute differently across physiological compartments. Water-soluble hydrophilic drugs like amoxicillin for dogs concentrate heavily in urine (often 50 to 100 times higher than serum levels) but fail to penetrate the blood-prostate, blood-brain, or blood-ocular barriers. Lipid-soluble drugs like fluoroquinolones (enrofloxacin (Baytril) for dogs and cats) or trimethoprim-sulfamethoxazole (TMS) penetrate deep tissues, the prostate, and intracellular niches.
3. Calculate distance from the clinical breakpoint (Not the lowest absolute MIC):
   • Compare the isolate's MIC to that specific drug's established CLSI susceptible breakpoint. An antibiotic with an MIC of 2.0 mcg/mL sitting four doubling dilutions below a breakpoint of 32 mcg/mL is pharmacodynamically "more susceptible" than a drug with an MIC of 0.25 mcg/mL sitting right at a breakpoint cutoff of 0.5 mcg/mL.
4. Apply guideline stewardship tiers before prescribing:
   • A susceptible result for a critically important antimicrobial (such as a fluoroquinolone or third-generation cephalosporin) does not mean you should bypass first-line empirical therapies. Under ISCAID consensus guidelines, first-line narrow-spectrum agents (such as amoxicillin for canine sporadic bacterial cystitis) take precedence whenever the isolate is susceptible.

       Veterinary Culture & Sensitivity Decision Hierarchy
┌─────────────────────────────────────────────────────────────┐
│ 1. ORGANISM & COUNT: True pathogen vs. contaminant/flora?   │
└──────────────────────────────┬──────────────────────────────┘
                               ▼
┌─────────────────────────────────────────────────────────────┐
│ 2. TISSUE PENETRATION: Hydrophilic vs. lipophilic barrier?  │
└──────────────────────────────┬──────────────────────────────┘
                               ▼
┌─────────────────────────────────────────────────────────────┐
│ 3. BREAKPOINT DISTANCE: How many dilutions below breakpoint?│
└──────────────────────────────┬──────────────────────────────┘
                               ▼
┌─────────────────────────────────────────────────────────────┐
│ 4. STEWARDSHIP TIER: Narrow-spectrum first-line preferred!  │
└─────────────────────────────────────────────────────────────┘

---

What does each part of the report mean—organism, MIC, and S/I/R?

A complete veterinary culture and susceptibility report contains four core informational components:

VETERINARY DIAGNOSTIC LABORATORY — MICROBIOLOGY REPORT
──────────────────────────────────────────────────────────────────────────
Patient: Canine, 6 yr FS, Labrador Retriever    Sample: Urine (Cystocentesis)
Source: Urinary Tract                           Clinical History: Dysuria, pollakiuria

ISOLATE IDENTIFICATION:
Organism: Escherichia coli
Colony Count: >100,000 CFU/mL (Pure culture)

ANTIMICROBIAL SUSCEPTIBILITY TESTING (Broth Microdilution)
──────────────────────────────────────────────────────────────────────────
Antimicrobial Agent       MIC (mcg/mL)    CLSI Breakpoint    Interpretation
Amoxicillin               <= 2            <= 8 / >= 32       S (Susceptible)
Amoxicillin-Clavulanate   <= 2 / 1        <= 8/4 / >= 32/16  S (Susceptible)
Cephalothin (Cefazolin)   <= 2            <= 8 / >= 32       S (Susceptible)
Cefpodoxime               <= 0.5          <= 2 / >= 8        S (Susceptible)
Enrofloxacin              <= 0.25         <= 0.5 / >= 2      S (Susceptible)
Marbofloxacin             <= 0.25         <= 1.0 / >= 4      S (Susceptible)
Trimethoprim-Sulfa (TMS)  <= 0.5 / 9.5    <= 2/38 / >= 4/76  S (Susceptible)
Doxycycline               > 8             <= 4 / >= 16       R (Resistant)
Gentamicin                <= 1            <= 4 / >= 16       S (Susceptible)
──────────────────────────────────────────────────────────────────────────
Method: CLSI VET01 broth microdilution. S = Susceptible; I = Intermediate; R = Resistant.

1. The Minimum Inhibitory Concentration (MIC)

The MIC is the lowest concentration of an antimicrobial agent (expressed in micrograms per milliliter, mcg/mL) that completely prevents visible in vitro growth of the bacterial isolate after standard incubation (usually 18 to 24 hours).

• Broth microdilution: The gold standard reference method where bacteria are inoculated into wells containing serial two-fold dilutions of the antibiotic (e.g., 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0 mcg/mL).
• The "<=" sign: Indicates that bacterial growth was inhibited at the lowest antibiotic concentration tested on the lab plate (e.g., <= 0.25 mcg/mL).
• The ">" sign: Indicates that the organism continued to grow even at the highest antibiotic concentration tested (e.g., > 8 mcg/mL), confirming marked resistance.

2. Clinical breakpoints (CLSI and EUCAST)

An MIC is merely an in vitro number. To determine whether that number translates into clinical cure in a living patient, standards organizations—primarily the Clinical and Laboratory Standards Institute (CLSI VET01 / VET09)—establish clinical breakpoints.

A clinical breakpoint is a specific concentration cutoff determined by integrating three distinct datasets:

1. Microbiological data: The wild-type MIC distribution of the bacterial species.
2. Pharmacokinetic/Pharmacodynamic (PK/PD) data: How the drug is absorbed, distributed, metabolized, and excreted in the target animal species at standard labeled dosages, evaluated against target parameters such as time above MIC (T>MIC) for beta-lactams or the peak-to-MIC and AUC-to-MIC ratios (Cmax/MIC, AUC/MIC) for aminoglycosides and fluoroquinolones.
3. Clinical outcome data: Observed clinical and microbiological cure rates in clinical trials.

3. The S / I / R interpretive categories

• S (Susceptible): There is a high probability of clinical and microbiological cure when the infection is treated with the standard labeled dosage regimen for that animal species and route of administration.
• I (Intermediate): The MIC approaches the achievable drug concentrations in blood and tissues. Treatment may still be clinically successful if higher labeled doses can be safely administered, or if the infection is located in a body site where the drug naturally concentrates to high levels (such as renally excreted drugs in the lower urinary tract).
• R (Resistant): The isolate is not inhibited by the achievable systemic drug concentrations with standard dosing schedules, or specific resistance mechanisms (such as beta-lactamase production or efflux pumps) are present. Clinical failure is expected.

---

Why is the drug with the lowest MIC often the wrong drug?

The single most prevalent misunderstanding in microbiology interpretation is directly comparing raw MIC numbers across different antibiotics.

The potency vs. breakpoint trap

Consider the published teaching example from a referral diagnostic laboratory (the Dick White Referrals MIC interpretation series), an Escherichia coli susceptibility panel showing two susceptible results:

• Marbofloxacin: MIC = 0.5 mcg/mL (susceptible breakpoint ≤ 1.0 mcg/mL)
• Amoxicillin-Clavulanate: MIC = 2.0 mcg/mL (susceptible breakpoint ≤ 8.0 mcg/mL)

An untrained reader might conclude: "0.5 is four times smaller than 2.0, so marbofloxacin is four times stronger and must be the better drug."

This conclusion is clinically false. Different antibiotics have fundamentally different chemical structures, molecular weights, standard dosing amounts, serum protein binding, and physiological tissue concentrations.

In the referral-laboratory example:

• Marbofloxacin at MIC = 0.5 mcg/mL sits only one dilution below its breakpoint (0.5 → 1.0).
• Amoxicillin-Clavulanate at MIC = 2.0 mcg/mL sits two dilutions below its breakpoint (2.0 → 4.0 → 8.0)—which is why the laboratory's own conclusion is that amoxicillin-clavulanate, not marbofloxacin, is the more sensitive option despite marbofloxacin's lower raw MIC. And when excreted in urine, active amoxicillin concentrations routinely exceed 200 to 500 mcg/mL, placing the drug many dilutions above the isolate's MIC.

Furthermore, prescribing marbofloxacin (a critically important third-generation fluoroquinolone) for an uncomplicated cystitis that readily responds to a first-line aminopenicillin violates veterinary antimicrobial stewardship principles, accelerating the selection of multidrug-resistant pathogens.

Dilution Distance from Susceptible Breakpoint Comparison
──────────────────────────────────────────────────────────────────────────
Drug A (Fluoroquinolone):
[0.25] ─── [0.50]* ─── [1.00 Breakpoint]          (1 dilution below)

Drug B (Aminopenicillin in Urine):
[0.50] ─── [1.00] ─── [2.00]* ─── [4.00] ─── [8.00 Breakpoint] (2 dilutions)
  │
  └─► In Urine: Peak concentration reaches >250 mcg/mL (MASSIVE margin!)
──────────────────────────────────────────────────────────────────────────
* Isolate MIC. Raw number comparison across drug classes is meaningless.

---

How are breakpoints set, and why do they differ between urine, skin, and blood?

Clinical breakpoints are not universal constants; they depend heavily on the anatomical site of infection.

Urine-specific vs. systemic tissue breakpoints

When an oral antibiotic is administered, serum and soft-tissue drug concentrations remain relatively modest to avoid systemic toxicity. However, drugs that are eliminated primarily by glomerular filtration and active tubular secretion concentrate heavily in the bladder:

• Ampicillin and Amoxicillin: Serum concentrations in dogs peak around 2 to 6 mcg/mL. In the bladder lumen, active urine concentrations routinely reach 100 to 400+ mcg/mL.
• Because of this physiological concentration, CLSI and ISCAID establish urine-specific breakpoints for ampicillin and amoxicillin in canine lower urinary tract infections (for example, a susceptible cutoff of ≤ 8 mcg/mL in urinary panels), whereas a soft tissue skin infection caused by an isolate with an MIC of 8 mcg/mL would be classified as resistant.

The tissue penetration barrier matrix

When evaluating a culture report, match the drug's pharmacokinetic properties to the infected tissue:

Anatomical Infection Site	Biological Barriers	Preferred Pharmacological Classes	Poorly Penetrating Classes
Lower Urinary Tract (Bladder)	High urine flow, mucosal barrier	Hydrophilic renally excreted drugs: Amoxicillin, Amox-Clav, Cephalexin, TMS	Doxycycline (fecal excretion), Macrolides
Prostate Gland	Blood-prostate barrier (lipid-rich, non-fenestrated)	Lipophilic, basic drugs: Fluoroquinolones (Enrofloxacin, Marbofloxacin), TMS, Chloramphenicol	Beta-lactams (Penicillins, Cephalosporins), Aminoglycosides
Central Nervous System (CNS)	Blood-brain barrier, tight junctions	Lipophilic drugs: Fluoroquinolones, Chloramphenicol, Metronidazole, 3rd-gen Cephalosporins	Penicillins, 1st-gen Cephalosporins, Aminoglycosides
Skin and Soft Tissue	Interstitial fluid diffusion	Cephalexin, Cefpodoxime, Amox-Clav, Clindamycin	Drugs with low soft-tissue partition coefficients
Bone and Joints (Osteomyelitis)	Cortical bone matrix, biofilm	Clindamycin, Fluoroquinolones, Doxycycline, Cephalosporins	Aminoglycosides (poor anaerobic/acidic bone activity)

---

What does intermediate actually mean, and when does it matter?

On a microbiology report, the "I" (Intermediate) category is frequently misunderstood as a failure.

According to CLSI veterinary guidelines, the intermediate category serves three vital clinical functions:

1. A biological and technical buffer zone: Minor laboratory test variations (such as pipetting differences or slight incubation temperature shifts) should not swing an interpretation wildly between susceptible and resistant.
2. Indication for dosage escalation: An intermediate result indicates that the pathogen can be inhibited if the clinician uses the higher end of the approved veterinary dosing range for a drug with a wide therapeutic index (for example, the upper end of cephalexin's labeled twice-daily range).
3. Exploitation of anatomical concentration: If an isolate from a canine cystitis case tests "Intermediate" to amoxicillin-clavulanate, clinical cure is still highly probable because urinary excretion delivers concentrations far exceeding the intermediate MIC cutoff. Conversely, an "Intermediate" result for a pneumonia or deep pyoderma case indicates that the drug should not be selected.

---

Real-world canine resistance rates behind the letters (NARMS 2017–2024 Data)

To understand what an "S" or "R" means in practice, clinicians must understand the underlying resistance epidemiology.

Based on our analysis of the FDA National Antimicrobial Resistance Monitoring System (NARMS) animal pathogen surveillance dataset (2017–2024, canine isolates, n=533,831 tests), resistance rates vary substantially across bacterial species and clinical sources:

1. Canine Escherichia coli (Urinary Tract Source, n ≈ 8,300–8,800 isolates per drug)

Antimicrobial Agent	NARMS Resistance Rate (%)	Susceptible Rate (%)	Clinical Interpretation Context
Enrofloxacin	14.1%	85.9%	Fluoroquinolone resistance in canine urinary E. coli sits near 14%; reserve for upper UTI or pyelonephritis.
Cefpodoxime	15.3%	84.7%	Oral 3rd-generation cephalosporin; moderate resistance; reserve for documented resistance.
Marbofloxacin	15.9%	84.1%	Closely parallels enrofloxacin resistance rates across surveillance centers.
Cefazolin (Cephalothin proxy)	13.8%	86.2%	Represents 1st-generation cephalosporins (Cephalexin); remains viable in >86% of isolates.
Tetracycline	13.1%	86.9%	Standard class marker for tetracyclines in surveillance panels.
Trimethoprim-Sulfa (TMS)	9.6%	90.4%	Highly effective first-line alternative; <10% resistance in canine urinary isolates.
Gentamicin	3.7%	96.3%	Aminoglycoside; exceptional susceptibility; reserved for hospitalized complicated/pyelonephritis cases.

Surveillance vs. Prevalence Note: NARMS data represents surveillance submissions from national diagnostic laboratories (NAHLN), which tend to oversample chronic, recurrent, or treatment-refractory cases compared to first-opinion general practice. True community first-episode resistance is typically lower.

2. Canine Staphylococcus pseudintermedius (Skin & Tissue Source, n ≈ 10,600–10,800 isolates per drug)

Staphylococcus pseudintermedius is the primary pathogen in canine pyoderma in dogs and otitis. The rise of Methicillin-Resistant S. pseudintermedius (MRSP) is tracked in surveillance panels via oxacillin resistance:

Canine MRSP Proxy (Oxacillin Resistance) Surveillance Trend (2017–2024)
──────────────────────────────────────────────────────────────────────────
Year    Tested Isolates (n)    Oxacillin Resistance (%)
2017    n = 431                31.3%  ████████████████
2018    n = 996                33.7%  █████████████████
2019    n = 1,501              39.5%  ████████████████████
2020    n = 1,519              36.9%  ██████████████████
2021    n = 1,576              37.3%  ███████████████████
2022    n = 1,587              39.3%  ████████████████████
2023    n = 1,652              42.9%  █████████████████████
2024    n = 1,490              43.0%  ██████████████████████
──────────────────────────────────────────────────────────────────────────
Overall Skin/Tissue-Source Oxacillin Resistance (2017–2024): 38.9% of 10,752

Other key canine S. pseudintermedius resistance rates:

• Cephalothin (1st-gen Cephalosporin proxy): 7.2% Resistant (92.8% Susceptible)—confirming that first-generation cephalosporins (Cephalexin, Cefazolin) remain highly effective for methicillin-susceptible pyoderma.
• Cefazolin: 9.9% Resistant.
• Clindamycin: 38.4% Resistant (macrolide/lincosamide resistance frequently co-segregates with MRSP).
• Trimethoprim-Sulfa: 35.7% Resistant.
• Enrofloxacin: 44.0% Resistant (Fluoroquinolones exhibit high cross-resistance in staphylococcal isolates; should never be used empirically for skin infections).

The Ampicillin Divergence Lesson: In the raw NARMS dataset, E. coli ampicillin resistance reads 33.1% across all non-specific anatomical sources, but only 1.5% in the dedicated urinary-tract subset. This massive divergence is an artifact of selective panel testing and reporting conventions across laboratories. Clinicians should interpret single-drug surveillance numbers in light of specific anatomical source subsets rather than aggregated headlines. For more details on resistance mechanisms, see antibiotic-resistant bacteria in dogs.

---

How do the report and ISCAID first-line guidelines fit together?

Consensus guidelines published by the International Society for Companion Animal Infectious Diseases (ISCAID) establish an evidence-based drug selection hierarchy. When a culture report arrives, use guidelines to pick the narrowest, most appropriate tier:

                   ISCAID Antimicrobial Stewardship Tiers
┌────────────────────────────────────────────────────────────────────────┐
│ FIRST-LINE / FIRST-TIER ANTIMICROBIALS                                 │
│ Canine Cystitis: Amoxicillin, Trimethoprim-Sulfa (TMS)                 │
│ Canine Pyoderma: Topical Chlorhexidine (1st), Cephalexin, Amox-Clav   │
│ Feline URI / CIRDC: Doxycycline, Amoxicillin                           │
└───────────────────────────────────┬────────────────────────────────────┘
                                    │ (Use if Susceptible)
                                    ▼
┌────────────────────────────────────────────────────────────────────────┐
│ SECOND-TIER / RESERVED ANTIMICROBIALS                                  │
│ Fluoroquinolones (Enrofloxacin, Marbofloxacin, Pradofloxacin)          │
│ 3rd-Gen Cephalosporins (Cefpodoxime, Cefovecin / Convenia)            │
│ Indication: Documented resistance to 1st-tier agents OR deep tissue/   │
│ pyelonephritis / systemic sepsis.                                      │
└───────────────────────────────────┬────────────────────────────────────┘
                                    │ (Severe Refractory Only)
                                    ▼
┌────────────────────────────────────────────────────────────────────────┐
│ THIRD-TIER / CRITICALLY IMPORTANT (Human-Shared Reserve)              │
│ Aminoglycosides (Amikacin, Gentamicin), Carbapenems, Vancomycin       │
│ Indication: Life-threatening multi-drug resistant (MDR) infections    │
│ with specialist consultation.                                          │
└────────────────────────────────────────────────────────────────────────┘

1. Canine urinary tract infections (ISCAID 2019 Guidelines)

• Sporadic bacterial cystitis: The recommended first-line empirical choice is Amoxicillin (11–15 mg/kg PO q12h for 3–5 days) or Trimethoprim-Sulfamethoxazole (15 mg/kg PO q12h).
• The Clavamox trap: Amoxicillin-clavulanate is rarely needed for initial uncomplicated cystitis because amoxicillin concentrates so heavily in urine that it overcomes low-level beta-lactamase production.
• Fluoroquinolones (Enrofloxacin, Marbofloxacin): Must be reserved for documented upper urinary tract infections (pyelonephritis), prostatic involvement, or isolates exhibiting confirmed resistance to all first-line options. For complete clinical management, see canine urinary tract infection.

2. Canine pyoderma (ISCAID 2025 Guidelines)

• Topical therapy first: Topical 2% to 4% chlorhexidine shampoos and sprays are the first-line treatment for superficial bacterial folliculitis, often eliminating the need for systemic oral antibiotics entirely.
• Systemic first-tier: If systemic therapy is necessary, Cephalexin (22–25 mg/kg PO q12h), Cefadroxil, Amoxicillin-Clavulanate, or Clindamycin (if susceptible) are primary choices.
• Third-generation cephalosporins (Cefpodoxime, Cefovecin/Convenia): Are second-tier agents reserved for cases where first-tier drugs are resistant or owner compliance makes oral administration impossible.

---

Report anomalies: Why some rows have no MIC and how to handle contaminants

1. Rows with no numerical MIC

• Kirby-Bauer Disk Diffusion: Some laboratories utilize agar disk diffusion, measuring the zone of bacterial inhibition in millimeters (mm) rather than broth dilutions. The report displays zone diameters and S/I/R calls without an MIC.
• Class Representative Testing: Standard laboratory panels do not test every commercial drug. Per CLSI standards, Cephalothin or Cefazolin serves as the laboratory surrogate for oral Cephalexin; Oxacillin serves as the surrogate for methicillin resistance; and Tetracycline predicts Doxycycline susceptibility for many organisms.
• Intrinsic (Innate) Resistance: Certain bacteria possess natural, chromosomal resistance mechanisms that render entire antibiotic classes ineffective regardless of in vitro numbers. For example:
  • Pseudomonas aeruginosa is intrinsically resistant to ampicillin, amoxicillin-clavulanate, first- and second-generation cephalosporins, trimethoprim-sulfa, chloramphenicol, and tetracyclines.
  • Enterococcus species are intrinsically resistant to cephalosporins, macrolides, clindamycin, and potentiated sulfonamides in vivo.

2. True pathogen vs. contaminant or normal flora

Before treating a positive culture, evaluate the sampling method:

Sample Collection Method	Normal Flora Expected?	Diagnostic Colony Count Threshold	Clinical Action
Cystocentesis (Urine)	No (Sterile)	≥ 1,000 CFU/mL (Pure culture)	True UTI; treat based on clinical signs.
Catheterized Urine	Low-level urethral flora	≥ 10,000 CFU/mL	Interpret with clinical sediment analysis.
Free-Catch (Voided Urine)	Yes (Distal urogenital flora)	≥ 100,000 CFU/mL	High contamination risk; repeat via cystocentesis if mixed growth.
Deep Tissue Biopsy (Aseptic)	No (Sterile)	Any significant growth	True infection.
Superficial Skin Swab / Ear	Heavy normal flora	Mixed flora common	Cytology must confirm intracellular bacteria before culturing (see dog ear cytology).

3. Subclinical bacteriuria: When NOT to treat

One of the most critical consensus recommendations from ISCAID is that subclinical bacteriuria (the presence of bacteria in the urine without clinical signs of dysuria, stranguria, hematuria, or pollakiuria) should NOT be treated with antibiotics in dogs and cats. Treating asymptomatic bacteria selects for resistant strains without providing clinical benefit. Culture results must always be interpreted alongside the patient's symptoms. For clinic-wide implementation, explore establishing an antimicrobial stewardship program for veterinary practices and reviewing diagnostic workflows such as fecal flotation versus antigen testing.

---

Frequently asked questions

Is a low MIC number always better than a high MIC number?

No. MIC numbers cannot be compared across different antibiotic classes. A drug with an MIC of 0.25 mcg/mL is not automatically better than a drug with an MIC of 2.0 mcg/mL. What matters is the drug's distance below its own specific CLSI clinical breakpoint, its ability to concentrate at the anatomical site of infection, and its place in antimicrobial stewardship guidelines.

What does susceptible mean on a culture report?

"Susceptible" means that the isolate's MIC is at or below the standardized clinical breakpoint for that drug. It indicates a high statistical probability of clinical and microbiological cure when the drug is administered at standard labeled dosages and intervals for that species. It is a pharmacokinetic probability statement, not an absolute guarantee.

Why does my report list antibiotics that my clinic never carries?

Microbiology testing panels are standardized by bacterial genus (e.g., Gram-negative enteric panels, Gram-positive staphylococcal panels) and regulatory standards, not by individual clinic formularies. Furthermore, some drugs appear as class representatives—for example, testing cephalothin informs the clinician about oral cephalexin susceptibility.

Can an antibiotic work clinically if the lab report says it is resistant?

Yes, in specific circumstances. Standard breakpoints are calibrated for systemic tissue concentrations. When treating a lower urinary tract infection with a renally excreted drug (such as amoxicillin), active concentrations in the bladder lumen can reach hundreds of times higher than serum levels, occasionally clearing an organism classified as in vitro "resistant" on systemic panels. However, deliberate selection of a resistant drug is not recommended when susceptible first-line alternatives exist.

---

Sources

• VET01: Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals — Clinical and Laboratory Standards Institute (CLSI). Authoritative international reference for veterinary antimicrobial susceptibility testing standards, broth microdilution protocols, and clinical breakpoint definitions.
• International Society for Companion Animal Infectious Diseases (ISCAID) Guidelines Hub — ISCAID. Official consensus guidelines for antimicrobial use in companion animal urinary tract disease (2019 update), respiratory tract disease (2017), and canine superficial pyoderma (2025).
• Antimicrobial use guidelines for canine pyoderma (ISCAID, 2025) — Loeffler A, Cain CL, Ferrer L, et al. Veterinary Dermatology (open access via PubMed Central). Consensus recommendations for topical-first therapy of superficial bacterial folliculitis and first-tier systemic agents (cefalexin 22–25 mg/kg PO q12h, cefadroxil, amoxicillin-clavulanate, clindamycin).
• Interpretation of MICs in Antibiotic Susceptibility Testing — Dick White Referrals Diagnostics Laboratory. Clinical laboratory guide illustrating breakpoint distance, site-of-infection penetration, and why the lowest MIC is not the superior drug choice.
• National Antimicrobial Resistance Monitoring System (NARMS) — FDA Center for Veterinary Medicine (CVM). Public database for animal pathogen resistance surveillance; source for 2017–2024 canine E. coli and S. pseudintermedius resistance benchmarks.
• Antimicrobial Use Guidelines for Treatment of Urinary Tract Infections in Dogs and Cats — Veterinary Microbiology / PubMed Central. Peer-reviewed ISCAID working group consensus on empirical antimicrobial selection, breakpoint application, and subclinical bacteriuria management.
• Culture and Sensitivity Laboratory Standards — Michigan State University Veterinary Diagnostic Laboratory (MSU VDL). Diagnostic laboratory reference on specimen submission, broth microdilution methods, and aerobic/anaerobic isolation protocols.
• Antimicrobial Stewardship Core Principles — American Veterinary Medical Association (AVMA). Professional consensus guidance on rational drug selection, diagnostic testing utilization, and resistance mitigation in veterinary practice.